Von E. needs a plan B
This article was originally published in The Tan Sheet
Executive Summary
A Senate Health Committee staffer believes it is "highly unlikely" that acting FDA Commissioner Andrew von Eschenbach will be confirmed this year. Sens. Hillary Clinton (D-N.Y.) and Patty Murray (D-Wash.) placed a hold on von Eschenbach's confirmation due to the agency's failure to provide a timeline for a decision on the over-the-counter switch application for Barr's emergency contraceptive Plan B (1"The Tan Sheet" April 3, 2006, p. 4)...
You may also be interested in...
Plan B Backlash Blocks FDA Commissioner Nomination: Take Two
FDA will not have a permanent commissioner until an actual decision is announced on the proposed Rx to-OTC switch of emergency contraceptive Plan B, if a hold by Senate Democrats is respected
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.